Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary
Open Access
- 28 January 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (1) , e9-e17
Abstract
Cancer of unknown primary (CUP) comprises a heterogeneous collection of malignancies that are typically associated with a poor prognosis and a lack of effective treatment options. We retrospectively evaluated the clinical utility of targeted next-generation sequencing (NGS) among CUP patients to assist with diagnosis and identify opportunities for molecularly guided therapy. Patients with a CUP at Moffitt Cancer Center who underwent NGS between January 1, 2014 and December 31, 2019, were eligible for study inclusion. Next-generation sequencing results were assessed to determine the frequency of clinically actionable molecular alterations, and chart reviews were performed to ascertain the number of patients receiving molecularly guided therapy. Ninety-five CUP patients were identified for analysis. Next-generation sequencing testing identified options for molecularly guided therapy for 55% (n = 52) of patients. Among patients with molecularly guided therapy options, 33% (n = 17) were prescribed a molecularly guided therapy. The median overall survival for those receiving molecularly guided therapy was 23.6 months. Among the evaluable patients, the median duration of treatment for CUP patients (n = 7) receiving molecular-guided therapy as a first-line therapy was 39 weeks. The median duration of treatment for CUP patients (n = 8) treated with molecularly guided therapy in the second- or later-line setting was 13 weeks. Next-generation sequencing results were found to be suggestive of a likely primary tumor type for 15% (n = 14) of patients. Next-generation sequencing results enabled the identification of treatment options in a majority of patients and assisted with the identification of a likely primary tumor type in a clinically meaningful subset of patients.Keywords
Funding Information
- Moffitt Cancer Center (P30-CA076292)
- NIH
- ASHP Foundation
This publication has 40 references indexed in Scilit:
- Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Comprehensive Genomic Profiling of Carcinoma of Unknown Primary SiteJAMA Oncology, 2015
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literatureCancer Treatment Reviews, 2013
- Massively‐parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primaryThe Journal of Pathology, 2013
- Site‐specific survival rates for cancer of unknown primary according to location of metastasesInternational Journal of Cancer, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Cancer of unknown primary siteThe Lancet, 2012
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory CancersJournal of Clinical Oncology, 2010
- Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysisCancer Treatment Reviews, 2009